Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Neurocrine Biosciences, Inc. on May 21, 2025. The filing details the outcomes of five matters submitted to a vote by security holders, including director elections, executive compensation, equity plans, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
As of the record date (March 24, 2025), 98,938,234 shares were entitled to vote, with 90,434,193 shares present. All five proposals were approved by stockholders:
- Director Elections: Four Class II Directors (Kyle W. Gano, Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin) were elected for three-year terms expiring in 2028. Notably, Richard F. Pops received a higher number of votes withheld (12,809,685) compared to the other nominees.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 77,981,925 votes for and 6,070,336 votes against.
- Equity Plans: Stockholders approved the 2025 Equity Incentive Plan and the amendment and restatement of the 2018 Employee Stock Purchase Plan.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves as a record of the completed Annual Meeting proceedings.
Important Facts for Investors to Verify
- Verify the specific terms and share limits of the newly approved 2025 Equity Incentive Plan and the Amended and Restated ESPP in the definitive proxy statement filed on April 9, 2025.
- Review the proxy statement for details regarding the significant number of votes withheld for director nominee Richard F. Pops.
- Confirm the composition of the Board of Directors, noting the staggered terms for Class I (expiring 2027) and Class III (expiring 2026) directors.